Lucite deal toy commemorating financing provided to ITM, a Munich-based biotech company. (25ALJ200)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Lucite deal toy commemorating financing provided to ITM, a Munich-based biotech company. (25ALJ200)
Crystal financial tombstone marking a public offering by Cellectar Biosciences. The New Jersey-based company will use the proceeds to fund a clinical study of a breast cancer drug. (25AKL244)
Custom crystal commemorating FDA approval of Gomekli, a treatment for the rare tumor disease ncurofibromatosis 1 (NF1). (25AZH094)
Crystal deal toy commemorating a follow-on stock offering by Oculis. The Swiss biopharmaceutical company provides treatment for eye conditions such as diabetic macula edema and acute optic neuritis. (25AKL187)
Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)
Logo-themed crystal financial tombstone commemorating a follow-on stock offering by Palisade Bio. The biopharmaceutical firm is based in Carlsbad, California. (25AKL019)
Custom crystal deal toy marking an investment in GXP-Storage. The Raleigh, North Carolina-based company provides storage for materials for life sciences and biomedical research. (25AZH003)
Custom Lucite deal toy, replicating a spray bottle product, commemorating a follow-on stock offering by Novabay Pharmaceuticals. The Emeryville, California-based biopharmaceutical company develops products for the eye care market. (24AKL343)
Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
